Cargando…

Survival and recurrence patterns of multifocal glioblastoma after radiation therapy

PURPOSE: It is hypothesized that multifocal glioblastoma (mGBM) is associated with worse prognosis compared to unifocal disease (uGBM). This study aims to investigate the differences in survival rates and progression patterns of patients between these two groups after radiation therapy. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Syed, Mustafa, Liermann, Jakob, Verma, Vivek, Bernhardt, Denise, Bougatf, Nina, Paul, Angela, Rieken, Stefan, Debus, Jürgen, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177520/
https://www.ncbi.nlm.nih.gov/pubmed/30323678
http://dx.doi.org/10.2147/CMAR.S165956
_version_ 1783361874533810176
author Syed, Mustafa
Liermann, Jakob
Verma, Vivek
Bernhardt, Denise
Bougatf, Nina
Paul, Angela
Rieken, Stefan
Debus, Jürgen
Adeberg, Sebastian
author_facet Syed, Mustafa
Liermann, Jakob
Verma, Vivek
Bernhardt, Denise
Bougatf, Nina
Paul, Angela
Rieken, Stefan
Debus, Jürgen
Adeberg, Sebastian
author_sort Syed, Mustafa
collection PubMed
description PURPOSE: It is hypothesized that multifocal glioblastoma (mGBM) is associated with worse prognosis compared to unifocal disease (uGBM). This study aims to investigate the differences in survival rates and progression patterns of patients between these two groups after radiation therapy. PATIENTS AND METHODS: We retrospectively analyzed 265 patients with primary GBM undergoing radiation therapy at the Department of Radiation Oncology, University Hospital Heidelberg, Germany, between 2004 and 2013. Of these, 202 (76%) were uGBMs and 63 (24%) were mGBMs. First, progression-free survival (PFS) and overall survival (OS) between groups were compared using the Kaplan–Meier method. Second, univariate and multivariate Cox proportional hazards regression was applied to discern prognostic and predictive factors with PFS and OS in the cohorts. Third, recurrence patterns of uGBMs and mGBMs were assessed on follow-up MRIs and compared using the chi-squared test. RESULTS: As compared to patients with uGBM, patients with mGBM experienced significantly worse median OS (11.5 vs 14.8 months, P=0.032). Overall, 195 (73.0%) patients experienced tumor progression: 153 (75.7%) patients with uGBM and 46 (73.0%) patients with mGBM. There were no significant differences in PFS between the respective groups (6.5 vs 6.6 months, P=0.750). Of note, concomitant temozolomide treatment was associated with an OS benefit in both uGBM and mGBM by about five months (P=0.006 and P<0.001). Furthermore, there were no significant differences in progression patterns of uGBM and mGBM. Both recurred as unifocal and multifocal disease (P=0.51), and local vs distant brain recurrences occurred similarly in both groups (OR=1.33, P=0.53). CONCLUSION: Multifocality is an independent predictor of survival in GBM. Concomitant temozolomide treatment improved OS of patients with mGBM and uGBM. Both disease types showed similar patterns of progression. Current target volume concepts seem to be adequate in both unifocal and multifocal GBMs. GBM, the most common primary brain tumor in adults, is associated with poor survival. We show herein that multifocality is an independent prognostic factor for survival. We also illustrate that the progression patterns of both unifocal and multifocal GBM are similar.
format Online
Article
Text
id pubmed-6177520
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61775202018-10-15 Survival and recurrence patterns of multifocal glioblastoma after radiation therapy Syed, Mustafa Liermann, Jakob Verma, Vivek Bernhardt, Denise Bougatf, Nina Paul, Angela Rieken, Stefan Debus, Jürgen Adeberg, Sebastian Cancer Manag Res Original Research PURPOSE: It is hypothesized that multifocal glioblastoma (mGBM) is associated with worse prognosis compared to unifocal disease (uGBM). This study aims to investigate the differences in survival rates and progression patterns of patients between these two groups after radiation therapy. PATIENTS AND METHODS: We retrospectively analyzed 265 patients with primary GBM undergoing radiation therapy at the Department of Radiation Oncology, University Hospital Heidelberg, Germany, between 2004 and 2013. Of these, 202 (76%) were uGBMs and 63 (24%) were mGBMs. First, progression-free survival (PFS) and overall survival (OS) between groups were compared using the Kaplan–Meier method. Second, univariate and multivariate Cox proportional hazards regression was applied to discern prognostic and predictive factors with PFS and OS in the cohorts. Third, recurrence patterns of uGBMs and mGBMs were assessed on follow-up MRIs and compared using the chi-squared test. RESULTS: As compared to patients with uGBM, patients with mGBM experienced significantly worse median OS (11.5 vs 14.8 months, P=0.032). Overall, 195 (73.0%) patients experienced tumor progression: 153 (75.7%) patients with uGBM and 46 (73.0%) patients with mGBM. There were no significant differences in PFS between the respective groups (6.5 vs 6.6 months, P=0.750). Of note, concomitant temozolomide treatment was associated with an OS benefit in both uGBM and mGBM by about five months (P=0.006 and P<0.001). Furthermore, there were no significant differences in progression patterns of uGBM and mGBM. Both recurred as unifocal and multifocal disease (P=0.51), and local vs distant brain recurrences occurred similarly in both groups (OR=1.33, P=0.53). CONCLUSION: Multifocality is an independent predictor of survival in GBM. Concomitant temozolomide treatment improved OS of patients with mGBM and uGBM. Both disease types showed similar patterns of progression. Current target volume concepts seem to be adequate in both unifocal and multifocal GBMs. GBM, the most common primary brain tumor in adults, is associated with poor survival. We show herein that multifocality is an independent prognostic factor for survival. We also illustrate that the progression patterns of both unifocal and multifocal GBM are similar. Dove Medical Press 2018-10-04 /pmc/articles/PMC6177520/ /pubmed/30323678 http://dx.doi.org/10.2147/CMAR.S165956 Text en © 2018 Syed et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Syed, Mustafa
Liermann, Jakob
Verma, Vivek
Bernhardt, Denise
Bougatf, Nina
Paul, Angela
Rieken, Stefan
Debus, Jürgen
Adeberg, Sebastian
Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title_full Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title_fullStr Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title_full_unstemmed Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title_short Survival and recurrence patterns of multifocal glioblastoma after radiation therapy
title_sort survival and recurrence patterns of multifocal glioblastoma after radiation therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6177520/
https://www.ncbi.nlm.nih.gov/pubmed/30323678
http://dx.doi.org/10.2147/CMAR.S165956
work_keys_str_mv AT syedmustafa survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT liermannjakob survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT vermavivek survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT bernhardtdenise survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT bougatfnina survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT paulangela survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT riekenstefan survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT debusjurgen survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy
AT adebergsebastian survivalandrecurrencepatternsofmultifocalglioblastomaafterradiationtherapy